ストックスクリーナーアプリを入手
1.03
1.98%
0.02
アフターアワーズ：
1.03
前日終値:
$1.01
開ける：
$1.03
24時間の取引高:
94,416
Relative Volume:
0.16
時価総額：
$11.97M
収益：
-
当期純損益:
$-10.93M
株価収益率:
-0.7164
EPS:
-1.4378
ネットキャッシュフロー:
$-10.72M
1週間 パフォーマンス:
-4.63%
1か月 パフォーマンス:
-5.50%
6か月 パフォーマンス:
-18.25%
1年 パフォーマンス:
-55.60%
1日の値動き範囲:
$1.025
$1.05
1週間の範囲:
$0.98
$1.08
52週間の値動き範囲:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
名前
Phio Pharmaceuticals Corp
セクター
電話
(508) 767-3861
住所
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.03 | 11.97M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-05 | 再開されました | H.C. Wainwright | Buy |
| 2020-08-05 | 開始されました | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp (PHIO) 最新ニュース
Phio Pharmaceuticals to present clinical updates on cancer treatment PH-762 at H.C. Wainwright conference - Pluang
A potential nonsurgical treatment for skin cancers will be discussed at an investor conference - Stock Titan
Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - Kalkine
Phio Pharmaceuticals Corp (PHIOW) Key Financial Ratios – Valuation, Profitability & More - Value Research
PHIO Should I Buy - Intellectia AI
Phio Pharmaceuticals director Plott buys $17,100 in shares - Investing.com
Phio Pharmaceuticals director Plott buys $17,100 in shares By Investing.com - Investing.com Canada
Phio Pharmaceuticals (PHIO) director snaps up 15,000 shares - stocktitan.net
Price to sales forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman Buys 10,00 - GuruFocus
Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares - Stock Titan
Price to earnings forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Price to earnings forward of Phio Pharmaceuticals Corp. – BOATS:PHIO - TradingView
Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026) - Stock Titan
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein - The National Law Review
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 - Investing.com
Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894 - Bitget
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 - TMX Newsfile
Phio Pharmaceuticals Receives U.S. Notice of Allowance for PH-894 Patent Targeting BRD4 Protein via INTASYL® Platform - kalkine.ca
Enterprise value to revenue forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Phio Pharmaceuticals Corp. Q2 2026: Net income $(4.14)M, EPS $(0.36) — 10-Q Summary - TradingView
Phio Pharmaceuticals posts $4.1M Q2 net loss, cash $13.0M; advances PH-762 program - TradingView
PHIO: PH-762 clinical progress accelerates as cash runway extends into 2027 amid rising R&D costs - TradingView
PHIO: Q2 2026 net loss widened to $4.1M as PH-762 advanced, with $13M in cash and ongoing funding needs - TradingView
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update - TMX Newsfile
Phio Pharmaceuticals advances PH-762 with comme... - Pluang
PHIO Q2'26 Earnings: EPS estimate is (0.36) USD - TradingView
Phio Pharmaceuticals (PHIO) Rises 2.91% as Shares Hold Above Key $1.01 SupportVolatility Skew - dars.gov.et
Phio Pharmaceuticals (NASDAQ:PHIO) secures patent milestone as PH-762 skin cancer program nears FDA meeting - Kalkine
PHIO Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals Corp (PHIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Phio Pharmaceuticals Corp (PHIO) Cash Flow - TradingKey
PHIO|Phio Pharmaceuticals Corp|Price:1.050| - TradingKey
TradingKey - TradingKey
Phio Pharmaceuticals Corp (PHIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Phio Pharmaceuticals Q1 2026 Earnings: Loss Widens as R&D Investments ContinueLow Estimate Range - vinanet.vn
Phio Pharmaceuticals Market Sentiment - Benzinga España
Phio Pharmaceuticals Corp. Revenue Breakdown – NASDAQ:PHIO - TradingView
PHIO|Phio Pharmaceuticals Corp|Price:1.040| - TradingKey
PHIO|Phio Pharmaceuticals Corp|Price:1.055|Chg%:+0.015 - TradingKey
Phio Pharmaceuticals (PHIO) Slightly Lower, Approaching Key Support at $0.99ETF Liquidity - vinanet.vn
Phio Pharmaceuticals (PHIO) Edges Higher, Testing Key Resistance at $1.13Sector ETF Flow - dars.gov.et
Phio Pharma corrects date for Renmark virtual non-deal roadshow presentation - Bitget
Phio Pharmaceuticals to present its INTASYL siR... - Pluang
Phio Pharmaceuticals CEO Robert Bitterman to Showcase INTASYL Gene Silencing Platform at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
Phio Pharmaceuticals to Showcase INTASYL siRNA Platform and PH-762 Skin Cancer Therapy at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
Phio Pharmaceuticals Appoints Dr. R. Todd Plott to Board of Directors, Strengthening Expertise in Dermatologic Research and Commercialization – Minichart - Minichart
Phio Pharmaceuticals appoints dermatologist to board By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Corp (PHIO) 財務データ
収益
当期純利益
現金流量
EPS
Phio Pharmaceuticals Corp (PHIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Aug 18 '26 |
Buy |
1.06 |
10,000 |
10,600 |
431,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Jun 26 '26 |
Buy |
0.99 |
10,000 |
9,900 |
421,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 31 '25 |
Buy |
1.03 |
5,000 |
5,150 |
291,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
0.24%
1.67%
大文字化:
|
ボリューム (24 時間):